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Background: The role of triglyceride (TG) in predicting the outcomes in diabetic patients with coronary artery
disease (CAD) has not been well investigated.
Methods: A total of 329 cases with stable angina pectoris (SAP) were prospectively enrolled and followed up for an
average of 12 months. They were classified into the two groups according to the cut-off values of predicting early
outcome of fasting TG level (low group <1.2 mmol/L, n = 103; High group ≥1.2 mmol/L, n = 226). The relationship
between the TG levels and early outcomes were evaluated.
Results: High TG group showed severer lipid profile and elevated inflammatory markers. During an average of
12-month follow-up, 47 out of 329 patients suffered from pre-specified outcomes. Area under the receivers
operating characteristic curve suggested that TG, similar to serum Hemoglobin A1C (HbA1C), was a significant
predictor of early outcome for diabetic patients with SAP (P = 0.002). In Cox regression models, after adjusted age,
gender, body mass index, other lipid parameters, fasting blood glucose, high sensitivity C-reactive protein,
neutrophil count and HbA1C, TG remained as an independent predictor of adverse prognosis.
Conclusions: High level of fasting TG (≥1.2 mmol/L) was an independent predictor for early outcome of diabetic
patients with SAP as like as HBA1c and number of affected coronary arteries in the era of revascularization and
statin therapeutics.
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Dyslipidemia is a hitherto well-known and pivotal risk
factor for development of coronary artery disease
(CAD). High levels of fasting triglyceride (TG) and low
levels of high-density lipoprotein cholesterol (HDL-C)
has long been regarded as potently atherogenic dyslipid-
emia in patients with and without diabetes mellitus
(DM) [1-5]. Meanwhile, it has been demonstrated that
concurrence of high fasting TG levels and low HDL-C
levels, generally expressed as index of atherogenic* Correspondence: lijianjun938@yahoo.com
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unless otherwise stated.dyslipidemia, was strongly associated with insulin
resistance or glucose metabolic intolerance and high
vulnerable to CAD [5-7]. In fact, several prospective epi-
demiological studies have reported that there are posi-
tive relationship between plasma TG concentration and
the risk of CAD, especially from date of univariate ana-
lysis. However, this association disappeared after adjust-
ing for HDL-C, low-density lipoprotein cholesterol
(LDL-C) or non-HDL-C by using the multivariate re-
gression models [8-10].
Meanwhile, the majority of evidence for elevated TG
level as an independent risk for CAD derived from trials
on primary prevention [10]. Several investigations on the
association of high levels of fasting TG between CAD and
its mortality has led to conflict results, especially in differ-
ent ethnic backgrounds of the secondary preventionhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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should be tailored at specified point for diabetic popula-
tion are largely unknown, as it may exhibit a more signifi-
cantly detrimental role even when present at relatively
“normal” levels while synergized with other dyslipidemia,
disorder of glucose metalism and inflammatory bio-
markers such as c-reactive protein (CRP) [1,18-22]. In
addition, although several studies has demonstrated the
positive correlation of high TG/HDL-C index and severity
of CAD but evidence regarding whether the high levels of
admission fasting TG could also provide any additional
prognostic information for diabetic patients with stable
CAD remained to be elucidated [20,23,24]. More import-
antly, the role of TG concentrations in predicting the clin-
ical outcomes in the era of revascularization and statin
therapeutics has currently not been established.
The aim of this study, therefore, was to prospectively
investigate the predictive ability of baseline fasting TG
levels for early outcome in Chinese Han diabetic patients
with stable angina pectoris (SAP) underwent coronary
angiography.
Methods
Patients population and study protocol
From June 2011 through March 2012, we prospectively
enrolled 329 consecutive patients (73.3% of males, aged
form 34 to 82 years with an average age of 59.3 years)
diagnosed with type 2 diabetic patients and typical stable
exertional angina pectoris referred for selective coronary
angiography at our center. Patients without significant
CAD and with type 1 diabetes mellitus, ACS, significant
hematologic disorders (white blood cell count ≤3.5×109/L
or ≥20×109/L), infectious or inflammatory disease, severe
liver and/or renal insufficiency were excluded from the
current study. All subjects enrolled were underwent de-
tailed clinical, hematologic and angiographic examination
for assessment of the cardiac status and were asked for
their present and past history about risk of traditional risk
factors of CAD such as smoking habits, hypertension,
hyperlipidemia, obesity, diabetes mellitus, previous stroke,
peripheral vascular disease, family history of CAD and
non-cardiovascular diseases.
Hypertension was defined as repeated blood pressure
measurements ≥140/90 mmHg and was assumed to be
present in patients taking anti-hypertensive drugs. Dia-
betes mellitus was diagnosed in patients with fasting
serum glucose level of ≥6.99 mmol/L in multiple deter-
minations or under active treatment with insulin or oral
hypoglycemic agents. Hyperlipidemia was considered to
be present in patients with fasting total cholesterol
(TC) ≥5.2 mmol/L or TG ≥1.7 mmol/L. CAD was de-
fined as the presence of significant obstructive stenosis,
at least 50% of the vessel lumen diameters, in any of the
main coronary arteries by at least two independentsenior interventional cardiologists based on quantity
coronary angiography (QCA). The severity of CAD was
scored as 1 (single vessel disease), 2 (two-vessel disease),
3 (three-vessel disease and/or left main stem disease
and/or equally affected of left anterior descending and
left circumflex branch). Stent implantation, periproce-
dural medical treatment and care were performed ac-
cording to standard criteria when there were indicative
of revascularization. Postinterventional antiplatelet ther-
apy consisted of clopidogrel and aspirin with formal dos-
age. Drug eluting stents were majorly implantation. The
left ventricular ejection fraction was evaluated by echo-
cardiograph using the area-length methods with modi-
fied Simpson’s rule.
The study complied with the Declaration of Helsinki,
and was approved by the hospital ethnic review board
(Fu Wai Hospital & National Center for Cardiovascular
Diseases, Beijing, China). Informed written consent was
obtained from all patients included in this analysis.Follow up and study endpoints
The follow up protocol after discharge consisted of a
phone or clinic interview. Patients were followed up for
an average of 12 months. The pre-specified clinical end
points were defined as cardiac causative death, nonfatal
MI, revascularization, and re-hospitalization due to at-
tack of acute coronary syndrome.Measurements of biomarkers
Venous blood samples were obtained from each patient at
baseline upon admission. TC and TG were measured by
enzymatic methods and HDL-C by a direct method (Roche
Diagnostics, Basel, Switzerland). LDL-C was obtained by
Friedewald’s formula (if fasting triglycerides < 3.39 mmol/l)
or by ultracentrifugation. ApoB was measured by an immu-
noturbidimetric method (Tina-quant, Roche Diagnostics)
calibrated against the World Health Organization/Inter-
national Federation of Clinical Chemistry reference stand-
ard SP3–07. The levels of hemoglobin A1c (HbA1c) were
measured using the Tosoh G7 Automate HPLC Analyzer
(TOSOH Bioscience, Japan). The TG/HDL-C index was
calculated from ratio of fasting TG to HDL-C ratio. Non-
HDL cholesterol was calculated by subtracting HDL choles-
terol from total cholesterol. LDL-C/HDL-C ratio expressed
the ratio of LDL-C and HDL-C. The levels of high-
sensitivity-CRP were determined using immunoturbidime-
try (Beckmann Assay 360, Bera, Calif., USA) according to
our previously reported. The median normal value for hs-
CRP is 0.8 mg/L, with 90% of normal values <0.3 mg/L,
and a lower detection limit of 0.2 mg/L. The inter-assay
and intra-assay coefficients of variation were <5%, respect-
ively. All other included biomarkers were analyzed by
standard hematological and biochemical tests.
Figure 1 Distribution of admission fasting triglycerides in the
study population.
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Quantitative variables were expressed as mean ± stand-
ard deviation (SD), and qualitative variables were
expressed as numbers and percentages. Continuous vari-
ables and categorical variables were analyzed by the two
group’s t test, or chi-squared statistic tests when appro-
priate. Receivers operating characteristic (ROC) curves
were constructed at the most discriminating cutoff point
values aimed to document the predictive power of fast-
ing triglycerides and other biomarkers for early outcome
in the study population. Based on the cutoff values of
admission fasting TG, the enrolled patients were classi-
fied into two groups (low group < 1.2 mmol/L, n = 103;
High group ≥ 1.2 mmol/L, n = 226). Predictive effect of
fasting TG and other biomarkers for 12-month out-
comes was carried by two multivariate Cox proportional
hazard models using forward stepwise selection process:
model one used crude values of fasting TG and HbA1c;
model two used tertiles of fasting TG and HbA1c.
Event-free survival curves were constructed using the
Kaplan-Meier methods and compared using log-rank
test. A p value of less than 0.05 was considered as statis-
tically significant. Statistical studies were carried out




The study population of current observation consisted of
329 diabetic patients underwent coronary angiography
with an average follow-up time of 12 months (ranged from
20 to 448 days). The baseline characteristics and laboratory
findings of the enrolled subjects by fasting TG distribution
(Figure 1) and cut-off values of predictive early outcome in
the study population (low group <1.2 mmol/L, n = 103;
high group ≥1.2 mmol/L, n = 236) were summarized in
Table 1 and Table 2. In brief, patients with higher TG
levels were middle aged, higher body mass index (BMI)
and accompanied with various other dyslipidemia and
abnormal fasting blood glucose. Meanwhile, the major
inflammatory and oxidative stress biomarkers such as
leucocytes count, uric acid between the two groups
showed significant unbalanced. However, levels of high
sensitivity CRP, fibrinogen, D-dimer, HbA1c and other
clinical characteristics such as involved numbers of af-
fected coronary artery, cases of underwent secondary
prevention and/or drug eluting stent implantation were
well matched.
Utility of TG for predicting early outcomes
During an average 12-month follow-up, 47 out of the
329 patients underwent adverse outcome (Figure 2).
There were significant associations among baseline TG
levels and incidence of total outcome, revascularization(P = 0.009 and 0.005, respectively), but not for nonfatal
MI or cardiac death (P = 0.697 and 0.185, respectively)
during the follow-up period. Area under the receivers
operating characteristic (ROC) curves (Figure 3 and
Table 3) suggested that baseline TG, beyond other lipid
parameters and nonspecific inflammatory biomarkers,
was a significant predictor for early outcome of dia-
betic patients with SAP (AUC = 0.64, 95% CI 0.57-0.72,
P = 0.002).Multivariate Cox proportional regression model and
Kaplan- Meier curves of TG for predicting early outcomes
Multivariate analysis by Cox regression models (Table 4,
model one using absolute values of admission fasting
TG and model two using tertiles of fasting TG that con-
trolled for major potential confounders (including age,
gender, BMI, traditional cardiovascular risk factors, other
lipid parameters and hematological index of differential
at baseline) suggested that, apart from numbers of af-
fected coronary arteries and serum HbA1C, fasting TG
was remained as an independent predictor for overall
outcome in patients with SAP (model one: HR = 1.29,
95% CI 1.01-3.93, P = 0.048; model two: HR = 1.53, 95%
CI 1.06-2.21, P = 0.025, respectively).
Kaplan-Meier curves for cumulative event-free survival
based on cutoff values of admission fasting triglycerides
were showed in Figure 4. High levels of serum fasting
TG (≥1.2 mmol/L) was associated with increased early
adverse outcome (Figure 4).
Table 1 Baseline demographic, clinical characteristics according to cut-off value of fasting triglycerides in the study
population
Variables Total Fasting triglycerides P-value
<1.2 mmol/L (N = 103) ≥1.2 mmol/L (N = 226)
Demographics
Age, years 59.3 ± 9.3 60.9 ± 9.6 58.7 ± 9.1 0.043
Male gender 241 (73.3) 77 (74.8) 164 (72.6) 0.677
Body mass index 25.5 ± 3.0 24.9 ± 3.0 25.7 ± 3.0 0.045
Risk factors
Current Smoking 181 (55.0) 59 (57.3) 122 (54.0) 0.577
Hypertension 221 (62.1) 64 (62.1) 157 (69.5) 0.189
Hyperlipidemia 263 (79.9) 76 (73.8) 187 (82.7) 0.060
Peripheral vascular disease 6 (1.8) 2 (1.9) 4 (1.8) 0.914
Prior Stroke 13 (4.0) 4 (3.9) 9 (4.0) 0.966
Family history of CAD 36 (10.9) 10 (9.7) 26 (11.5) 0.628
Angiographic findings 0.481
1-vessel disease 96 (29.2) 30 (29.1) 66 (29.2)
2-vessel disease 80 (24.3) 21 (20.4) 59 (26.1)
3-vessel disease 153 (46.5) 52 (50.5) 101 (44.7)
LVEF (%) 62.0 ± 8.3 61.8 ± 8.8 62.1 ± 8.1 0.749
Medical treatment
Aspirin 321 (97.6) 100 (97.1) 221 (97.8) 0.702
Clopidogrel 315 (95.7) 100 (97.1) 215 (95.1) 0.415
Beta-blocker 271 (82.7) 79 (76.7) 193 (85.4) 0.053
ACE-I 85 (25.8) 29 (28.2) 56 (24.8) 0.516
Statin 320 (97.3) 101 (98.1) 219 (96.9) 0.551
DES implantation 67 (20.4) 22 (21.4) 45 (19.9) 0.762
CAD Coronary artery disease, LV-EF Left ventricular ejection fraction, ACE-I Angiotensin converting enzyme inhibitors, DES Drug eluting stent.
Li et al. Lipids in Health and Disease 2014, 13:73 Page 4 of 9
http://www.lipidworld.com/content/13/1/73Discussion
As far as our knowledge, this was the first study among
Chinese type 2 diabetes with stable CAD to demonstrate
that fasting TG on admission was an useful predictor for
adverse outcomes independent of other traditional prog-
nostic variables in the era of revascularization and statin
therapy. The main findings of the present study are
threefold. First, according to baseline characteristics of
the current study, patients with higher fasting TG levels
(≥1.2 mmol/L) were more prominent at groups of mid-
dle aged and higher BMI. Moreover, patients at high TG
groups prone to be accompanied with other various dys-
lipidemia, impaired fasting glucose, high levels of inflam-
matory and oxidative response biomarkers such as
leucocyte count, neutrophil count and uric acid. Second,
in agreement with previous studies, as showed in ROC
curves and bar graphs, our data further demonstrated
that elevated fasting TG levels might be conferred to a
useful discriminator for the presence of adverse events
in diabetic patients with SAP. Third, both chi-squared
for trend and multivariate Cox proportional regressionanalysis after adjusted major potential confounders were
consistently indicated that fasting TG could provide with
prognostic information in diabetic population with stable
CAD and remained as an independent predictor for
early outcome. Kaplan-Meier curve for cumulative
event-free survival indicated that the high levels of TG
were associated with increased adverse prognosis al-
though the rate of statin administration and stent
implantation were not different between the groups. Ap-
parently, the present study not only confirmed the previ-
ous studies but also provided the novel information
concerning the role of TG in predicting early outcomes
in diabetic patients with stable CAD, especially in the
era of revascularization and statin therapy.
Several lines of evidence have revealed a positive rela-
tion between TG and CAD and clinical outcomes in
patients with or without diabetes owing to the role of TG-
rich lipoproteins in atherothrombosis. The Copenhagen
Male Study, which followed 2,906 white men over 8 years,
demonstrated that fasting TG was independently associ-
ated with the incidence of CAD [25]. Data from Multiple
Table 2 Baseline laboratory characteristics according to cut-off value of serum Triglycerides in the study population
Variables Total Fasting triglycerides P-value
<1.2 mmol/L (N = 103) ≥2 mmol/L (N = 226)
Biochemical markers
hs-CRP (mg/L) 3.2 ± 4.1 3.5 ± 4.5 3.1 ± 3.9 0.440
Leucocyte count (109/L) 6.5 ± 1.6 6.2 ± 1.5 6.6 ± 1.6 0.048
Neutrophil count (109/L) 3.8 ± 1.2 3.6 ± 1.1 3.9 ± 1.2 0.041
Neutrophil/lymphocyte ratio 2.2 ± 1.1 2.1 ± 1.0 2.2 ± 1.1 0.530
Fasting blood glucose (mmol/L) 6.1 ± 2.2 5.7 ± 1.9 6.3 ± 2.3 0.025
Hemoglobin A1C (%) 6.9 ± 1.4 6.7 ± 1.3 6.9 ± 1.4 0.149
D-dimer (ug/mL) 0.4 ± 0.5 0.4 ± 0.6 0.4 ± 0.4 0.252
Fibrinogen (g/L) 3.1 ± 0.8 3.1 ± 0.8 3.1 ± 0.9 0.644
Endothelin-1 (fmol/ml) 0.6 ± 0.3 0.6 ± 0.3 0.6 ± 0.3 0.587
Alkaline phosphatase (IU/L) 63.5 ± 18.6 62.0 ± 20.1 64.2 ± 17.9 0.318
Uric acid (mmol/L) 338.3 ± 78.9 314.9 ± 75.9 348.9 ± 78.1 0.000
Creatinine (umol/L) 76.3 ± 15.6 74. 4 ± 14.0 77.2 ± 16.2 0.138
Lipid profile
Total cholesterol (mmol/L) 4.0 ± 1.0 3.5 ± 0.8 4.2 ± 1.1 0.000
LDL-C (mmol/L) 2.4 ± 0.9 2.1 ± 0.7 2.5 ± 0.9 0.000
HDL-C (mmol/L) 1.1 ± 0.3 1.1 ± 0.3 1.0 ± 0.3 0.002
Lipoprotein (a) (mg/L) 244.4 ± 244.5 267.9 ± 218.9 233.6 ± 254.9 0.237
apoA(g/L) 1.4 ± 0.3 1.4 ± 0.3 1.4 ± 0.3 0.477
apoB(g/L) 1.0 ± 0.3 0.9 ± 0.2 1.1 ± 0.3 0.000
TG/HDL-C index 1.7 ± 1.3 0.8 ± 0.3 2.2 ± 1.3 0.000
Non-HDL-C (mmol/L) 2.9 ± 0.9 2.4 ± 0.7 3.1 ± 0.9 0.000
LDL-C/HDL-C ratio 2.3 ± 0.8 1.9 ± 0.7 2.4 ± 0.8 0.000
hs-CRP high sensitivity C-reactive protein, LDL-C Low density lipoprotein cholesterol, HDL-C High density lipoprotein cholesterol, Non-HDL-C Non-High density
lipoprotein cholesterol = Total cholesterol subtracts to high density lipoprotein cholesterol, TG/HDL-C index Triglycerides/high density lipoprotein cholesterol ratio,
LDL-C/HDL-C ratio Low density lipoprotein cholesterol/High density lipoprotein cholesterol ratio.
Figure 2 Correlation of admission fasting triglycerides and 12-month outcome.
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Figure 3 ROC curves showed discriminatory power of baseline
serum Triglycerides and hemoglobin A1c on early outcome of
the study population.
Table 3 Comparison of AUC among lipid profiles, glucose
intolerance parameters and inflammatory biomarkers for
predicted early outcome in the study population
Variables AUC 95% CI P-value
Lipid profiles
Fasting triglycerides 0.64 0.57-0.72 0.002
TG/HDL-C index 0.62 0.54-0.69 0.012
ApoB 0.58 0.49-0.67 0.076
Non-HDL-C 0.56 0.46-0.65 0.230
LDL-C/HDL-C ratio 0.55 0.46-0.64 0.252
ApoA 0.54 0.45-0.64 0.363
Total cholesterol 0.53 0.44-0.63 0.470
LDL-C 0.53 0.44-0.63 0.495
HDL-C 0.49 0.40-0.59 0.935
Parameters of glucose intolerance
Hemoglobin A1C 0.62 0.54-0.71 0.007
Fasting blood glucose 0.61 0.52-0.70 0.013
Inflammatory biomarkers
hs-CRP 0.55 0.46-0.63 0.293
Neutrophil count 0.53 0.44-0.61 0.557
TG/HDL-C index Triglycerides/high density lipoprotein cholesterol index,
Non-HDL-C Non-High density lipoprotein cholesterol = Total cholesterol subtracts
to high density lipoprotein cholesterol, LDL-C/HDL-C ratio Low density lipoprotein
cholesterol/High density lipoprotein cholesterol ratio, LDL-C Low density lipoprotein
cholesterol, HDL-C High density lipoprotein cholesterol, hs-CRP high sensitivity
C-reactive protein.
Table 4 Cox proportional regression of Multivariate
adjusted for independent predictors of 12-month total
outcome
Variables HR 95% CI P-value
Model 1
Triglycerides 1.29 1.01-3.93 0.048
Hemoglobin A1C 1.34 1.12-1.45 0.001
Numbers of affected coronary arteries 1.69 1.19-1.69 0.009
Model 2
First tertile of triglycerde (reference) 1.00
Second tertile of triglycerde 2.75 1.15-6.60 0.023
Third tertile of triglyceride 3.13 1.34-7.32 0.008
Numbers of affected coronary arteries 1.59 1.16-2.20 0.004
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fasting or fasting TG is an independent risk factor for
CAD [26]. Several mata-analyses showed that high con-
centration of TG was an independent risk factor for the
morbidity and mortality rates of CAD in primary preven-
tion [8-10]. Moreover, the Action to Control Cardiovascu-
lar Risk in Diabetes (ACCORD) study detected that
combination therapy using lipid-lowering drugs for regu-
lating both LDL-C and TG could lead to a significant
benefit in patients with metabolic syndrome but not to
those without [4]. Recently, Kasai et al. observed 1836 pa-
tients who underwent complete revascularization between
1984 and 1992, and evaluated the association between
fasting TG level and all-cause and cardiac mortality for a
median follow-up of 10.5-year period [16]. They foundFigure 4 Kaplan-Meier curve for 12-month cumulative event-free
survival based on cutoff value of baseline serum Triglycerides.
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creased risk of cardiac death after complete coronary re-
vascularization. However, they did not demonstrated that
there were significant associations of age, gender, presence
of diabetes, levels of TC and HDL-C, the use of statins
with all-cause and cardiac death in their subgroup
analysis.
The disparities of our data from their study were sum-
marized as followings: firstly, their patients were enrolled
between 1984 and 1992 duration in which optimal
pharmacological therapy for CAD was not widely per-
formed clinically. Besides, prior cases were subjected to
percutaneous coronary intervention (PCI) with simple
balloon angioplasty, and no patients received stent im-
plantation; Finally, the population received coronary ar-
tery bypass grafting (CABG) in previous studies were as
higher as 32%. In current study, including subjects were
confined at diabetic patients with an relatively short-
term duration (from June 2011 through March 2012).
Among studied population, majority of patients were re-
ceived statin therapeutics, and their profiles of major
lipid disorders were significantly improved such as per-
fect of targeted LDL-C. We affirmed that baseline fasting
TG was a powerful predictor for early outcome in dia-
betic patients with stable CAD, similar to the evidence
from American Heart Association which has recently
suggested that the independent predictive values of TG
levels as a causal factor in development of CAD remains
as debatable [27]. Obviously, our study extended previ-
ous studies in that data provided the vital prognostic in-
formation regarding the role of fasting TG in diabetic
subjects with stable CAD.
At the same time, our data suggested that patients
with higher levels of admission fasting TG were more
prone to receive revascularizations. The underlying hy-
pothesis of current results might be consisted in three
aspects. To begin with, high levels of fasting TG were
not only implied with the severe disorder of glycolipid
metabolism, but also low-grade of systematic inflamma-
tory response, vascular dysfunction and potentially
atherosclerotic progress in these settings [2,28-31]. Sec-
ondly, with the advent of statin therapeutic era, the directly
pivotal role of LDL-C on the atherogenesis has been favor-
ably controlled (an average of LDL-C = 2.4 ± 0.9 mmol/L in
the studied population). Nonetheless, It has been reported
that the residual risks of atherogenic dyslipidemia have
been increasingly prominent and gradually emerged as a
leading impeller of cardiovascular disease and its future
event [32,33]. Therefore, the badly impacts of TG were not
adjusted by multivariable analysis especially in the patients
received of successfully complete revascularization and
ideal glycemic control. Regarding to the current study
population, all patients who had indications of revascu-
larization were received complete intervention. Thirdly,several prior studies about secondary prevention of
fasting TG had led to very similar results about the HR
values (approximate to 1.5) [16,34]. Although those
study population had different background of demo-
graphics and comorbidities, the reproducible of above
result strikingly supported the consistent hypothesis
that TG was an independent predictor of adverse out-
come. Fourthly, epidemical cohorts about primary pre-
vention also suggested a direct association between
relatively high levels of TG and incidence of CAD and
mortality [8-10]. Finally, our findings also supported the
viewpoint that high levels of TG might be very probably
to have potential impacts on the vasculature before the
establishments of formal diagnosis for hypertriglyc-
eridemia and led to fasting glucose impaired and/or
overt atherosclerosis disease alone or coupled with
other risk biomarkers [30,32,35].
Nonetheless, the limitations of our study are obvious.
First of all, the sample scale of the current study was rela-
tively small and enrolled patients were entirely Chinese
Han population. Besides, the duration of follow-up period
was comparably in short term and unavoidably led to
the bias for totally observing the outcome. Furthermore,
the main method of revascularization of present investi-
gation was confined to drug eluting stent implantation
and although it might be mostly analogous to the real
world of China, it inevitably implied with high incidence
of target vascular revascularization. Besides, as the uni-
versal utilization of statin therapeutics, it will be difficult
to deploy a subset analysis on the effect of statin
therapy. Finally, our investigation failed to compare
the predictive values of fasting and non-fasting TG at
these settings.
Taken together, although TG was a paradox marker all
along, the results of our study clearly suggested that high
level of fasting TG (≥1.2 mmol/L) was an independent
indicator of early outcome for diabetic patients with SAP
as like as HBA1c and number of affected coronary arteries.
Whether should be set a strict target value of fasting TG
specifically for diabetic population with stable CAD aimed
to reverse the “atypical atherogenic dyslipidemia” need to
be seriously considered.Abbreviations
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